[Desperately seeking targets].
In clinical oncology, obtaining sequence data from tumour samples has become practical in terms of logistics, turnover time and costs. The major issue now is the interpretation of this sequence to define actionable targets, i.e. genome changes that are involved in tumorogenesis and that predict the efficacy of existing and available targeted treatments. This is the focus of major efforts from public clinical centres and from companies that see it as a promising commercial activity.
UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France ; CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
Bertrand
B
Jordan
D000465:Algorithms; D002173:Cancer Care Facilities / Q000458:organization & administration; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004252:DNA Mutational Analysis / Q000379:methods; D004273:DNA, Neoplasm / Q000235:genetics; D015195:Drug Design; D055088:Early Detection of Cancer; D052138:Genes, Neoplasm; D016147:Genes, Tumor Suppressor; D005820:Genetic Testing / Q000191:economics / Q000379:methods; D019981:Health Care Sector / Q000458:organization & administration; D006801:Humans; D008495:Medical Oncology / Q000191:economics / Q000379:methods* / Q000639:trends; D058990:Molecular Targeted Therapy; D060885:Multiplex Polymerase Chain Reaction / Q000379:methods; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D057285:Precision Medicine / Q000379:methods* / Q000639:trends; D017422:Sequence Analysis, DNA
D004273:DNA, Neoplasm; D009363:Neoplasm Proteins